1. Folkman J, 1971. Tumor angiogenesis: therapeutic implications. N. Eng. J. Med. 285: 1182-1186
2. Lau LF, and Nathans D, 1985. Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells. EMBO J. 4: 3145–3151
3. Lau LF, and Lam SC, 1999. The CCN family of angiogenic regulators: the integrin connection. Exp. Cell Res. 248: 44–57
4. Babic AM, Kireeva ML, Kolesnikova TV, and Lau LF, 1998. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc. Natl. Acad. Sci.USA 95: 6355-6360
5. Babic AM, Chen CC, and Lau LF, 1999. Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol. Cell. Biol. 19: 2958-2966
6. Lin C, Leu S-J, Chen N, Tebeau CM, Lin S-X, Yeung C-Y, and Lau LF, 2003. CCN3 (Nov) is a novel angiogenic regulator of the CCN protein family. J. Biol. Chem.  278: 24200-24208
7. Mo F-E, Muntean AG, Chen C-C, Stolz DB, Watkins SC, and Lau LF, 2002. CYR61 (CCN1) is essential for placental development and vascular integrity. Molec. Cell. Biol. 22: 8709-8720
8. Chen C-C, Mo F-E, and Lau LF, 2001. The angiogenic factor Cyr61 activates a genetic program for wound healing in primary human skin fibroblasts. J. Biol. Chem. 276: 47329-47337
9. O’Brien TP, and Lau LF, 1992. Expression of the growth factor-inducible immediate early gene cyr61 correlates with chondrogenesis during mouse embryonic development. Cell Growth and Differentiation 3: 645-654
10. Latinkic BV, Mo F-E, Greenspan JA, Copeland NG, Gilbert DJ, Jenkins NA, Ross SR, and Lau LF, 2001. Promoter function of the angiogenic inducer cyr61 gene in transgenic mice: tissue specificity, inducibility during wound healing, and role of the serum response element. Endocrinology 142: 2549-2557
11. Tsai MS, Bogart DF, Castaneda JM, Li P, and Lupu R, 2002. Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 21: 8178-8185. & Menendez JA, Vellon L, Mehmi I, Teng PK, GriggsDW, and Lupu R, 2005. A novel Cyr61-triggered “Cyr61-alpha3betav integrin loop’ regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene 24: 761-779.
12. Nguyen N, Kuliopulos K, Graham RA, and Covic L, 2006. Tumor derived Cyr61[CCN1] promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells. Cancer Research 66; 2658-2667
13. Zhou D, Herrick DJ, Rosenbloom J, and Chaqour B, 2005. Cyr61 mediates the expression of VEGF,alphav-integrin, and alpha-actin genes through cytoskeletally based mechanotransduction mechanisms in bladder smooth muscle cells. J. Appl. Physiol. 2005 98: 2344-2354
14. Kunz M, Moeller S, Koczan D, Lorenz P, Wenger RH, Glocker MO, Thiesen H-J, Gross G, and Ibrahim SM, 2003. Mechanisms of hypoxic gene regulation of angiogenesis factor Cyr61 in melanoma cells. J. Biol. Chem., 278; 45651-45660
15. Gashaw I, Stiller S, Boing C, Kimmig R, and Winterhager E, 2008. Premenstrual regulation of the pro-angiogenic factor CYR61 in human endometrium. Endocrinology 149: 2261-2269
16. Lin J, Huo R, Wang L, Zhou Z, Sun Y, Shen B, Wang R, and Li N, 2012. A novel anti-Cyr61 antibody inhibits breast cancer Growth and metastasis in vivo. Cancer Immunol. Immunother. 61: 677-687
17. Chintalapudi MR, et al., 2008. Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL-mutant melanoma cells. Carcinogenesis 29: 696-703
18. Meyuhas R, et al., 2008. A key role for cyclic AMP-responsive element binding protein in hypoxia-mediated activation of the angiogenesis factor CCN1 in tumor cells. Mol. Cancer Res 6: 1397-1409
19. Lin MT, et al., 2008. Involvement of hypoxia-induced factor-1 alpha-dependent plasminogen activator inhibitor-1 up=regulation in Cyr61-induced gastric cancer cell invasion. J. Biol. Chem. 283: 15807-15815
20. Hirschfeld M, et al., 2009. Alternative splicing of Cyr61 is regulated by hypoxia and significantly changed in breast cancer. Cancer Res. 69: 2082-2090    
21. Hirschfeld M, et al., 2011. Expression of tumor-promoting Cyr61 is regulated by hTRA2-beta 1 and acidosis. Human Mol. Genet. 20: 2356-2365
22. Vasudev, NS and Reynolds, AR, 2014. Anti-angiogenic therapy for cancer: current progress, unresolved questions, and future directions. Angiogenesis 17:471-494
23. Welti J, Loges S, Dimmeler S, Cameliet P, 2013. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 123 (8):3190-3200